In 2020, the pharmaceutical industry raced to develop shots against a deadly new virus sweeping the globe — and succeeded, in record time. They did it while navigating the pandemic themselves, managing operations and supply chains amid profound disruption. By the end of 2020 deal activity rose to a borderline fever pitch describes Goodwin’s Stuart Cable, vice chairman and chair of mergers and acquisitions. Read the Bloomberg article here.
In The Press January 11, 2021